Starling Oncology, Inc.
STLN· Nasdaq
STLNStarling Oncology, Inc.
Filed May 28, 2021 · 10-Q · 58 days after period end · 0001104659-21-073662
| Metric | Q1 2021 | Q1 2020 |
|---|---|---|
| Revenue | $48.58M | — |
| Net Income | $5.69M | -$45.09K |
| EPS Diluted | -$0.02 | — |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Starling Oncology, Inc. · CIK 1799191 · Engraved from SEC EDGAR
ended Mar 31, 2021 · filed May 28, 2021 · 58 d after period end
